Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does protein binding influence lipitor's removal via kidneys?What's the recommended schedule for lurbinectedin side effect checks?How does insurance coverage impact nivolumab's duration?When will tenofovir alafenide come off patent in canada?Prolia and osteonecrosis?
See the DrugPatentWatch profile for eliquis
Eliquis is the brand name for apixaban, an oral anticoagulant used to prevent and treat blood clots.[1]
Bristol-Myers Squibb and Pfizer co-developed and market Eliquis (apixaban).[1]
Key U.S. patents for apixaban expired in 2023, but pediatric exclusivity extended market protection to February 2026. Generic entry faces ongoing litigation from multiple challengers.2 [1]: https://www.drugs.com/medical-answers/eliquis-generic-3571159/ [2]: https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
Other Questions About Eliquis :